BYD Made the Fortune Global 500 List for 2022
On August 3rd, BYD made the Fortune Global 500 list for 2022, demonstrating its outstanding achievements in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005487/en/
BYD made the Fortune Global 500 list for 2022 (Photo: Business Wire)
Focusing on solving social problems, BYD remains dedicated to leveraging effective solutions for sustainable development. After years of progress, BYD has grown into a high-tech enterprise with its business scope covering automobiles, rail transit, new energy, and electronics. In pursuit of a greener world, BYD becomes a Fortune Global 500 enterprise that furnishes new energy overall solutions.
Amidst the backdrop of the recent rapid growth of the automobile industry, BYD leverages its strengths to usher in advanced technology, high quality products, and broader markets. Backed by its technologies, such as the Blade Battery, DM-i super hybrid technology, and the e-platform, BYD sold 730,093 passenger vehicles in 2021, including 593,745 new energy passenger vehicles, with a YoY increase of 231.6%. In China, BYD has cemented its status as the top seller of new energy passenger vehicles for nine consecutive years. In the first half of 2022, BYD sold 638,157 new energy passenger vehicles, up 324.8% YoY.
BYD has its sights set far beyond China. In the process of expanding the global footprint, BYD always embraces technological revolution and industrial transformation around the world. By incorporating global wisdom and sharing green technological innovations with consumers, BYD is on the path to be internationally competitive. Currently, BYD’s new energy vehicle footprint extends to over 400 cities and across 70 countries and regions on 6 continents. On July 21, BYD announced its official entry into the passenger vehicle market in Japan, marking a new chapter in the globalization of BYD passenger vehicles.
Since March 2022, BYD has ceased the production of cars powered only by internal combustion engines. Its shift to only producing battery electric vehicles and plug-in hybrid electric vehicles epitomizes the low-carbon transformation in the transportation industry.
At present, carbon emission reduction and new energy development are the global consensuses. As an international high-tech company, BYD is committed to providing new energy solutions worldwide. Exceeding its prestigious Global 500 status, BYD will continue to create technological innovations for a better life, promote sustainable development of society, and implement its Cool the Earth by 1℃ initiative.
BYD (Build Your Dreams) is a multinational high-tech company devoted to leveraging technological innovations for a better life. BYD now has four industries including Auto, Electronics, New Energy, and Rail Transit. Since its foundation in 1995, the company quickly developed solid expertise in rechargeable batteries and has become a relentless advocate of sustainable development, successfully expanding its renewable energy solutions globally with operations in over 70 countries and regions. Its creation of a Zero Emissions Energy Ecosystem, comprising affordable solar power generation, reliable energy storage, and cutting-edge electrified transportation, has made it an industry leader in the energy and transportation sectors. BYD is a Warren Buffet-backed company and is listed both on the Hong Kong and Shenzhen Stock Exchanges. More information on the company can be found at http://www.byd.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Asia-Pacific: Mia Gu, email@example.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, firstname.lastname@example.org tel: +1 213 245 6503
Latin America: Sofίa Mardones, email@example.com tel: +56 9 9821 6851
Brazil: Adalberto Maluf, firstname.lastname@example.org tel: +19 3514 2554
Africa: Nikki Li, email@example.com tel: +86-18938862670
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release
Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r
Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release
Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with
Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release
Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom